Cargando…
Gene delivery using AAV8 in vivo for disease stabilization in a bimodal gene therapy approach for the treatment of ADA-deficient SCID
Adenosine deaminase (ADA) deficiency is an inborn error of metabolism affecting multiple systems and causing severe combined immunodeficiency. We tested intravenous administration of recombinant adeno-associated virus (AAV) 2/8-ADA vector in ADA-deficient neonate and adult mice or as part of a bimod...
Autores principales: | Carbonaro-Sarracino, Denise A., Chun, Krista, Clark, Danielle N., Kaufman, Michael L., Jin, Xiangyang, Wang, Xiaoyan, Kohn, Donald B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940710/ https://www.ncbi.nlm.nih.gov/pubmed/33738330 http://dx.doi.org/10.1016/j.omtm.2021.02.007 |
Ejemplares similares
-
Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice
por: Carbonaro-Sarracino, Denise A., et al.
Publicado: (2019) -
Evaluation of clonal hematopoiesis in pediatric ADA-SCID gene therapy participants
por: White, Shanna L., et al.
Publicado: (2022) -
Review of Treatment for Adenosine Deaminase Deficiency (ADA) Severe Combined Immunodeficiency (SCID)
por: Secord, Elizabeth, et al.
Publicado: (2022) -
Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones
por: Uchiyama, Toru, et al.
Publicado: (2021) -
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy
por: Igarashi, Yuka, et al.
Publicado: (2017)